Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing effective delivery systems for Chlamydia vaccines.

Joseph U Igietseme1, Francis O Eko, Qing He

  • 1National Center for Infectious Disease, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. jigietseme@cdc.gov

Current Opinion in Molecular Therapeutics
|June 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A VCG-Based Multiepitope <i>Chlamydia</i> Vaccine Incorporating the Cholera Toxin A1 Subunit (MECA) Confers Protective Immunity Against Transcervical Challenge.

Biomedicines·2025
Same author

Role of route of delivery on Chlamydia abortus vaccine-induced immune responses and genital tract immunity in mice.

Microbes and infection·2024
Same author

In silico design and analysis of a multiepitope vaccine against Chlamydia.

Pathogens and disease·2024
Same author

A novel cold-chain free VCG-based subunit vaccine protects against <i>Chlamydia abortus</i>-induced neonatal mortality in a pregnant mouse model.

Frontiers in immunology·2023
Same author

Genital tract microbiome dynamics are associated with time of Chlamydia infection in mice.

Scientific reports·2023
Same author

The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency.

African journal of laboratory medicine·2023

Developing an effective Chlamydia vaccine is crucial for preventing serious diseases. Researchers face challenges in defining protective immunity, selecting antigens, and creating advanced delivery systems for long-lasting protection.

Area of Science:

  • * Infectious Diseases
  • * Immunology
  • * Vaccinology

Background:

  • * Chlamydia infections cause significant global health issues, including blindness, infertility, and chronic diseases.
  • * Current treatments are limited, highlighting the need for a prophylactic vaccine.
  • * Developing an effective Chlamydia vaccine presents multifaceted scientific challenges.

Purpose of the Study:

  • * To review the key challenges in Chlamydia vaccine development.
  • * To highlight advancements in antigen selection and delivery systems.
  • * To discuss strategies for achieving long-lasting protective immunity.

Main Methods:

  • * Review of current scientific literature on Chlamydia vaccine research.
  • * Analysis of challenges in defining protective immunity and vaccine evaluation.

Related Experiment Videos

  • * Examination of novel antigen discovery and delivery system development.

    • Main Results:

    • * Significant progress is being made in developing novel vaccine delivery systems (e.g., DNA, viral vectors, bacterial systems).
    • * Innovative immunomodulatory strategies are being explored to enhance vaccine efficacy.
    • * Adjuvant and delivery system development remains a critical challenge for long-term immunity.

    Conclusions:

    • * Overcoming challenges in immunity definition, antigen selection, and delivery systems is key to an effective Chlamydia vaccine.
    • * Advances in novel delivery systems and immunomodulatory strategies offer promise for future vaccine development.
    • * An efficacious Chlamydia vaccine is anticipated in the near future due to ongoing research efforts.